FDA Grants Orphan Drug Status to Ra Pharma’s Zilucoplan as Potential MG Treatment
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to zilucoplan, Ra Pharmaceuticals‘ lead candidate for the treatment of myasthenia gravis (MG). This status helps to support the potential therapy’s development by granting Ra Pharma certain incentives. Zilucoplan, formerly known as RA101495, is an…